The course of fibrinolytic proteins in children with malignant bone tumours

European Journal of Pediatrics, Supplement

Volumn 158, Issue 3, 1999, Pages

  Nowak Gottl U ^b   Munchow N ^a   Klippel, U ^b   Paulussen, M ^b   Bielack, S ^a   Ullrich, K ^b   Ehrenforth, S ^c  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^c UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

Bone tumours in children; LMWH; Plasminogen activators

Indexed keywords

ANTITHROMBIN; BLOOD CLOTTING FACTOR 5; ENOXAPARIN; LIPOPROTEIN A; LOW MOLECULAR WEIGHT HEPARIN; PLASMINOGEN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN C; PROTEIN S; TISSUE PLASMINOGEN ACTIVATOR; UROKINASE;

ADOLESCENT; ARTICLE; BONE CANCER; CHILD; EWING SARCOMA; FEMALE; FIBRINOLYSIS; FOLLOW UP; GENETIC RISK; HEPARINIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; OSTEOSARCOMA; POSTOPERATIVE COMPLICATION; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; RISK FACTOR; TREATMENT OUTCOME;

EID: 0342948899     PISSN: 09439676     EISSN: None     Source Type: Journal    
DOI: 10.1007/pl00014343     Document Type: Article

References (17)

1. Bashar H, Urano T, Fukuta K, Pietrazek MH, Hata M, Suzuki K, Kawabe K, Takada Y, Takada A (1994) Plasminogen activators and plasminogen activator inhibitor 1 in urinary tract cancer. Urol Int 52:4-8
2. Carrel A, Burrows MT (1911) Cultivation in vitro of malignant tumors. J Exp Med 13:571-575
3. Ganesh S, Sier CFM, Griffin G, Vloedgraven IJM, de Boer A, Welvaart K, van de Velde CJH (1994) Prognostic relevance of plasminogen activators and their inhibitors in colorectal cancer. Cancer Res 54:4065-4071
4. Goldhaber P, Cornman I, Ormsbee RA (1947) Experimental alteration of the ability of tumor cells to lyse plasma clots in vitro. Proc Soc Exp Biol Med 66:590-595
5. Jänicke F, Schmitt M, Graeff H (1991) Clinical relevance of urokinase-type and tissue-type plasminogen activators and their type 1 inhibitor in breast cancer Sem Thromb Haemost 17:303-312
6. Jänicke F, Schmitt M, Pache L, Ulm K, Harbeck N, Hölfer H, Graeff H (1993) Urokinase (uPA) and its inhibitor PAI-1 are strong and independent prognostic factors in node-negative breast cancer. Breast Cancer Res Treat 24:195-208
7. Lambert RA, Hanes FM (1911) Characteristics of growth of sarcoma and carcinoma cultivated in vitro. J Exp Med 13:495-504
8. Kono S, Rao JS, Bruner JM, Sawaya R (1994) Immuno-histochemical localization of plasminogen activator inhibitor type 1 in human brain tumors. J Neuropathol Exp Neurol 53:256-262
9. Nekarda N, Schmitt M, Ulm K, Wenninger A, Vogelsang H, Becker K, Roder JD, Fink U, Siewert JR (1994) Prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in completely resected gastric cancer. Cancer Res 54:2900-2907
10. Nowak-Göttl U, Debus O, Findeisen M, Kassenböhmer R, Koch HG, Pollmann H, Postler C, Weber P, Vielhaber H (1997) Lipoprotein(a): its role in childhood thromboembolism. Pediatrics (electronic pages) 99/6e11
11. Nowak-Göttl U, Koch HG, Aschka I, Kohlhase B, Vielhaber H, Kurlemann G, Kehl G, Jürgens H, Schneppenheim R (1996) Resistance to activated protein C (APCR) in children with venous or arterial thromboembolism. Br J Haematol 92:992-998
12. Nowak-Göttl U, Schaudin E, Hoffmann C, Eckhoff-Donovan S, Mertes N, Winkelmann W, Jürgens H (1995) Intraoperative clotting factor dilution and activated hemostasis in children with Ewing's sarcoma or osteosarcoma: A prospective longitudinal study. Haematologica 80:311-317
13. Papport H, Gardsvoll H, Romer J, Pedersen AN, Brünner N (1995) Plasminogen activator inhibitor type 1 in cancer: therapeutic and prognostic implications. Biol Chem Hoppe-Seyler 376:259-267
14. Pedersen H, Brünner N, Francis D, Oszerlind K, Ronne E, Hansen HH, Dano K, Grondahl-Hansen J (1994) Prognostic impact of urokinase, urokinase receptor and type 1 plasminogen activator inhibitor in squamous and large cell lung cancer tissue. Cancer Res 54:4671-4675
15. Ronne E, Hoyer-Hansen G, Brünner N, Pedersen H, Rank F, Osborne CK, Clark GM, Dano K, Grondahl-Hansen J (1995) Urokinase receptor in breast cancer tissue extracts. Enzyme-linked immunosorbent assay with a combination of mono-and polyclonal antibodies. Breast Cancer Res Treat 33:199-207
16. Vielhaber H, Kehl HG, Kececioglu D, Vogt J, Nowak-Göttl U (1996) Enhanced soluble thrombomodulin, t-PA and u-PA concentrations caused by short-term endothelial damage during percutaneous cardiac catheterisation. Fibrinolysis 10/2:47-49
17. Yoshida E, Verrusio EN, Mihara H, Oh DY, Kwaan HC (1997) Thrombin stimulates expression of the receptor for urokinase-type plasminogen activator in DU-145 prostate cancer cells. Fibrinolysis & Proteolysis 11:147-150